SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Sick Visit — Irène Joliot-Curie

PatientIrène Joliot-Curie
Date of birth1968-09-12
IdentifiersMRN HR-RB003-SYN; SSN (made up) 000-03-8841
Document date2026-10-08
AuthorSolène Marchand-Ellis, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Nausea, two episodes of vomiting, and no bowel movement for four days. [S]

History of Present Illness

Mrs. Joliot-Curie called this morning and was seen the same day, on day 11 of her first cycle of azacitidine with venetoclax. For three days she has felt queasy for most of the day, and she vomited twice yesterday, about an hour after her evening meal; the venetoclax tablets had been taken with breakfast and stayed down. She has had no bowel movement for four days and feels bloated, without severe pain. She has checked her temperature twice a day as instructed; the highest was 37.4 °C. She has had no chills, cough, sore throat, mouth sores, painful urination, diarrhea, or rectal pain. Her gums ooze a little when she brushes, and she has new small bruises on her shins. She is drinking about a liter and a half a day. She takes posaconazole, acyclovir, levofloxacin and allopurinol as prescribed. [S]

ElementDetail
OnsetThree days ago
CharacterConstant nausea; vomiting twice after the evening meal; no stool for four days, with bloating
SeverityModerate; eating about half her usual amount
ContextDay 11 of cycle 1 of azacitidine with venetoclax; profound neutropenia expected
Associated signs and symptomsNo fever (highest 37.4 °C); gum oozing and new bruises

Review of Systems

SystemResultFinding
ConstitutionalPositiveTired; no fever or chills
Ears, nose, mouth, and throatPositiveGums ooze on brushing; no mouth sores or sore throat
RespiratoryNegativeNo cough or breathlessness
GastrointestinalPositiveNausea, vomiting twice, constipation and bloating; no abdominal pain, diarrhea, rectal pain or bleeding
GenitourinaryNegativeNo painful urination
IntegumentaryPositiveSmall bruises on both shins; no rash
NeurologicalNegativeNo headache or confusion

7 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Azacitidine 115 mg (75 mg/m2) under the skin once daily on days 1 to 7 of each 28-day cycleOnce daily on days 1 to 7 of each 28-day cycleSubcutaneous route2026-09-28activeS
Venetoclax 10 mg oral tablet, cycle 1: 10 mg on day 1 and 20 mg on day 2, then two tablets (20 mg) daily with the 50 mg tablet from day 4 (70 mg a day, reduced for posaconazole)Ramp-up, then two tablets daily with the 50 mg tablet, with food and waterOral route2026-09-28 to 2026-10-19completedS
Venetoclax 50 mg oral tablet, cycle 1: one tablet alone on day 3 (50 mg), then one tablet daily with two 10 mg tablets from day 4 (70 mg a day)One tablet daily from day 3, with food and waterOral route2026-09-28 to 2026-10-19completedS
Posaconazole 100 mg delayed-release tablet, three tablets (300 mg) twice on day 1, then three tablets once daily, as antifungal prophylaxis while neutropenic300 mg twice on day 1, then 300 mg once daily with foodOral route2026-09-28activeS
Acyclovir 400 mg oral tablet, one tablet twice daily as herpes simplex and zoster prophylaxisOne tablet twice dailyOral route2026-09-28activeS
Levofloxacin 500 mg oral tablet, one tablet daily while the neutrophil count is below 0.5One tablet daily during profound neutropeniaOral route2026-09-28 to 2026-10-30completedS
Allopurinol 300 mg oral tablet, one tablet daily for tumor lysis prophylaxis during cycle 1One tablet dailyOral route2026-09-28 to 2026-10-19completedS
Ondansetron 4 mg orally disintegrating tablet, one tablet every 8 hours as needed for nauseaOne tablet every 8 hours as neededOral route2026-10-08activeS
Polyethylene glycol 3350, 17 g powder in a glass of water once daily17 g once daily, held for loose stoolsOral route2026-10-08activeS
Sennosides 8.6 mg oral tablet, two tablets at bedtimeTwo tablets at bedtimeOral route2026-10-08 to 2026-10-19completedS
Potassium chloride 20 mEq extended-release tablet, one tablet twice daily for three daysOne tablet twice daily for three daysOral route2026-10-08 to 2026-10-11completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-10-08Body height163cmS
2026-10-08Body weight52.4kgS
2026-10-08Body mass index (BMI) [Ratio]19.7kg/m2S
2026-10-08Systolic blood pressure106mm[Hg]S
2026-10-08Diastolic blood pressure64mm[Hg]S
2026-10-08Heart rate98/minS
2026-10-08Respiratory rate16/minS
2026-10-08Body temperature37.2CelS
2026-10-08Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-10-08Leukocytes [#/volume] in Blood by Automated count0.710*3/uL4-11 10*3/uLLowS
2026-10-08Neutrophils [#/volume] in Blood by Automated count0.110*3/uL1.5-7.5 10*3/uLLowS
2026-10-08Hemoglobin [Mass/volume] in Blood7.4g/dL12-15.5 g/dLLowS
2026-10-08Platelets [#/volume] in Blood by Automated count910*3/uL150-400 10*3/uLLowS
2026-10-08Sodium [Moles/volume] in Serum or Plasma137mmol/L135-145 mmol/LNormalS
2026-10-08Potassium [Moles/volume] in Serum or Plasma3.3mmol/L3.5-5.1 mmol/LLowS
2026-10-08Creatinine [Mass/volume] in Serum or Plasma0.84mg/dL0.57-1 mg/dLNormalS
2026-10-08Magnesium [Mass/volume] in Serum or Plasma1.8mg/dL1.7-2.2 mg/dLNormalS
2026-10-08Q-T interval corrected446msAbove 460 ms is prolonged in womenNormalS

Physical Exam

Vital signs recorded on 2026-10-08; see the Vital Signs section. [S]

SystemFinding
GeneralTired but alert; temperature 37.2 °C, pulse 98, blood pressure 106/64, oxygen saturation 97% on room air; weight 52.4 kg, down 1.1 kg
MouthDry mucous membranes; a few gum petechiae; no ulcers or thrush
SkinScattered petechiae and small bruises on both shins; injection sites on the abdomen healing
RespiratoryClear to auscultation
AbdomenMildly distended and soft, with active bowel sounds; no tenderness or guarding. No rectal examination while neutropenic

Problems

ProblemClinical statusVerificationCodeProvenance
Two months of tiredness, easy bruising and bleeding gums, with pancytopenia and 12 percent blasts on the blood smear; acute leukemia suspected and urgent hematology review bookedresolvedconfirmed D61.818S — Synthetic presenting concern at the index visit, superseded by the bone marrow diagnosis two days later; its timing echoes the documented decline in her health (D).
Acute myeloid leukemia diagnosed on bone marrow biopsy (34 percent myeloblasts), in a physicist with decades of occupational exposure to ionizing radiation; synthetic modern diagnosis linked to her documented leukemiaactiveconfirmed C92.00S — Synthetic modern diagnosis and subtype; the type of her real leukemia is not documented.
Occupational exposure to ionizing radiation over about four decades: X-ray work early in her career, laboratory work with polonium and other radioactive sources, and a laboratory accident in which a sealed polonium source ruptured on her bench about ten years agoactiveconfirmed Z57.1S — Synthetic modern coding of her documented occupational exposure.
Pulmonary tuberculosis in her forties, treated to completion; no symptoms of active diseaseactiveconfirmed Z86.11S — Synthetic modern coding of her documented tuberculosis; the treatment details are synthetic.
Moderately reduced lung gas transfer (DLCO 58 percent of predicted, FEV1 76 percent) from old tuberculous scarring of the right upper lobe; with performance status 2, it makes her unfit for intensive inductionactiveconfirmed R94.2S — Synthetic finding on pre-treatment testing.
Nausea with vomiting and constipation on day 11 of cycle 1 of azacitidine with venetoclax, without fever, with mild low potassium; managed as an outpatient; resolvedactiveconfirmed R11.2S — Synthetic treatment side effect; not a historical claim.

Assessment and Plan

Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia, Version 5.2026 (2026); NCCN Clinical Practice Guidelines in Oncology: Prevention and Treatment of Cancer-Related Infections (2026); Carson JL, et al. Red Blood Cell Transfusion: 2023 AABB International Guidelines. JAMA 2023 (PMID 37824153) (2023); Kaufman RM, et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med 2015 (PMID 25383671) (2015); Hesketh PJ, et al. Antiemetics: ASCO Guideline Update. J Clin Oncol 2020 (PMID 32658626) (2020)

Follow-up: Nurse phone call tomorrow. Blood count and potassium in three days. Bone marrow and review on day 22. Go to the emergency department at once for a temperature of 38.0 °C or more, abdominal pain, bleeding that does not stop, or vomiting that prevents taking her tablets. Next scheduled visit 2026-10-19: day 22 of cycle 1: bone marrow response, transfusion and infection review, and stopping venetoclax for count recovery. [S]